1Rehman Y, Rosenberg JE. Abiraterone acetate : oral androgen bio- synthesis inhibitor for treatment of castration - resistantprostate cancer[ J]. Drug Des Devel Ther,2012,6 : 13 - 18.
2Rehman Y, Rosenberg JE. Abiraterone acetate : oral androgen bio- synthesis inhibitor for treatment of castration - resistantprostate cancer [ J ]. Drug Des Devel Ther,2012,6 : 13 - 18.
3Ryan C J, Smith MR, Fong L, et al. Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration - resistant prostate cancer who received prior ketoconazole therapy[ J ]. J Clin Oncol,2010,28 (9) : 1481 - 1488.
4Attard G, Reid AH, A "Hem R, et al. Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration - resistant prostate cancer [ J ]. J Clin Oneol, 2009,27(23) :3742 - 3748.
5Danila DC, Morris M J, de Bono JS, et al. Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with doeetaxel - treated castration - resistant prostate cancer [ J ]. J Clin Onco1,2010,28 (9) : 1496 - 501.
6de Bono JS, Logothetis C J, Molina A, et al. Abiraterone and in- creased survival in metastatic prostate cancer [ J ]. N Engl J Med, 2011,364 (21) : 1995 - 2005.
7Fizazi K, Seher HI, Molina A, et al. Abiraterone acetate for treat- ment of metastatic castration - resistant prostate cancer : final over- all survival analysis of the COU -AA -301 randomised, double - blind, placebo - controlled phase 3 study [ J ]. Lancet Oneol, 2012,13(10) :983 -992.
8Logothetis C J, Basch E, Molina A, et al. Effect of abiraterone ac- etate and prednisone compared with placebo and prednisone on pain control and skeletal -related events in patients with metastat- ic castration - resistant prostate cancer: exploratory analysis of data from the COU - AA - 301 randomised trim [ J ]. Lancet Oneol, 2012,13(12) :1210 - 1217.
